Investment Rating - The report does not provide a specific investment rating for the human vaccine industry Core Insights - The human vaccine industry in China has experienced significant growth, with the market size increasing from 53.547 billion RMB in 2019 to 151.171 billion RMB in 2023, representing a compound annual growth rate (CAGR) of 29.62%. It is projected to grow from 178.448 billion RMB in 2024 to 303.112 billion RMB by 2028, with a CAGR of 14.16% [23][24] Industry Definition - Vaccines are biological products containing immunogenic substances that induce specific, active, and protective host immunity to prevent infectious diseases [3][4] Industry Classification - Vaccines are classified into two categories: Class I vaccines (government-provided and mandatory for citizens) and Class II vaccines (voluntary and self-paid) [4] Industry Characteristics - The human vaccine industry employs diversified business models to adapt to changing market demands and drive innovation. Domestic vaccines are expected to gradually expand into international markets, becoming global public health products [5][6] Development History - The development of human vaccines in China has progressed through three stages, with the technology evolving from first-generation to third-generation vaccines, including the approval of new vaccines like HPV [7][8] Industry Scale - The human vaccine industry market size has grown significantly, with a historical increase attributed to favorable policies and technological advancements. The market is expected to continue expanding due to the approval of new vaccines and increased vaccination awareness [23][24] Policy Analysis - Various policies have been implemented to enhance vaccine accessibility and encourage vaccination among high-risk groups, such as the elderly and children [20][26] Competitive Landscape - The human vaccine industry features a tiered competitive structure, with leading companies like Zhifei Biological and others in the second and third tiers. The market is shifting towards domestic vaccines due to increased innovation and supportive government policies [30][31] Export Growth - China's vaccine exports have surged, particularly after 2020, with export values rising from approximately 1.88 billion RMB in 2020 to about 6.45 billion RMB in 2022, reflecting a CAGR of 50.7% from 2020 to 2022 [25][32] Future Trends - The mRNA vaccine market is expected to grow, with domestic companies increasingly focusing on research and development to expand their product lines and capabilities [33]
人用疫苗：国产替代与大品种放量并行 头豹词条报告系列
Tou Bao Yan Jiu Yuan·2024-11-08 12:06